TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clinuvel Pharmaceuticals ( (AU:CUV) ) has issued an announcement.
Clinuvel Pharmaceuticals Limited announced the cessation of 36,323 performance rights due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth prospects.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on developing and commercializing treatments for severe skin disorders. The company is known for its innovative therapies and has a market focus on providing solutions for conditions related to skin pigmentation and photoprotection.
Average Trading Volume: 140,787
Technical Sentiment Signal: Sell
Current Market Cap: A$601.5M
For detailed information about CUV stock, go to TipRanks’ Stock Analysis page.